Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 37

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 37
---
, which means the market value of our common
stock that are held by non-affiliates exceeds $700 million as of the last business day of our prior second fiscal quarter, and (ii) the
date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

In addition, Section 107 of the JOBS Act also
provides that an emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided
in Section 7(a)(2)(B) of the Securities Act of 1933, as long as it is an emerging growth company. An emerging growth company
can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period, which means that when a standard is issued or revised and it has different application dates for public or private
companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.

Corporate Information

Our principal executive offices are located at
225 NE Mizner Blvd, Suite 640, Boca Raton, FL 33432. Our telephone number is (858) 964-3720. We maintain an Internet website at www.inmunebio.com.
The information contained on, connected to or that can be accessed via our website is not part of this prospectus. We have included our
website address in this prospectus as an inactive textual reference only and not as an active hyperlink.

<div align='center'>4

RISK FACTORS</div>

Investing in our securities involves a high degree
of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described in our
most recent Annual Report on Form 10-K, as supplemented and updated by subsequent quarterly reports on Form 10-Q and current reports on
Form 8-K that we have filed or will file with the